

**2024 Condition- and Procedure-Specific Mortality/Complication
Measures Supplemental Methodology Report**

**Stroke
Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee
Arthroplasty (TKA)**

Submitted By:

Yale New Haven Health Services Corporation — Center for Outcomes Research and Evaluation
(YNHHSC/CORE)

Prepared For:

Centers for Medicare & Medicaid Services (CMS)

March 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. EXECUTIVE SUMMARY | 6 |
| 2. BACKGROUND AND OBJECTIVES..... | 7 |
| 2.1. Importance of Including MA Beneficiaries in Hospital Outcome Measures..... | 7 |
| 2.2. Importance of Risk Adjustment Model Changes | 7 |
| 2.3. Objectives | 7 |
| 3. METHODS | 8 |
| 3.1. Data Sources | 8 |
| 3.2. Cohort and Outcomes..... | 9 |
| 3.3. Risk Model Reselection | 9 |
| 3.4. Statistical Analyses..... | 10 |
| 4. RESULTS | 11 |
| 4.1. Stroke Mortality Results | 11 |
| Stroke Admission Volume and Observed Mortality Rate | 11 |
| Frequency of Stroke Risk Variables..... | 11 |
| Stroke Model Performance..... | 17 |
| Risk-Standardized Mortality Rates for Stroke..... | 17 |
| Measure Reliability for Stroke | 18 |
| Change in Hospital Performance for Stroke | 19 |
| 4.2. Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) Complication Results | 21 |
| THA/TKA Admission Volume and Observed Complication Rate..... | 21 |
| Frequency of THA/TKA Risk Variables..... | 21 |
| THA/TKA Model Performance | 25 |
| Risk-Standardized Complication Rates for THA/TKA | 25 |
| Measure Reliability for THA/TKA | 26 |
| Change in Hospital Performance for THA/TKA | 27 |
| 5. REFERENCES | 29 |

List of Tables

| | |
|--|----|
| Table 3.1: Claim Type Codes | 9 |
| Table 4.1.1: Number of Admissions and Observed 30-Day Mortality Rate for Stroke, FFS versus MA Admissions, CY 2022..... | 11 |
| Table 4.1.2: Frequency of CC-Based Risk Variables in the Stroke Cohort, FFS versus MA Admissions, CY 2022..... | 12 |
| Table 4.1.3: Frequency of ICD-10-Based Risk Variables in the Stroke Cohort, FFS versus MA Admissions, and Adjusted OR and 95% Confidence Intervals for the Stroke Hierarchical Logistic Regression Model Using FFS+MA Admissions, CY 2022 | 13 |
| Table 4.1.4: Stroke Mortality: Predictive Ability and C-Statistics Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022..... | 17 |
| Table 4.1.5: Stroke Mortality: Hospital Volume, Standardized Mortality Ratio (SMR), and Risk-Standardized Mortality Rate (RSMR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for All Hospitals | 18 |
| Table 4.1.6: Stroke Mortality: Hospital Volume, Standardized Mortality Ratio (SMR), and Risk-Standardized Mortality Rate (RSMR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions | 18 |
| Table 4.1.7: Stroke Mortality: Between Hospital Variance and Signal-to-Noise Reliability (STNR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions | 19 |
| Table 4.1.8: Shifts in RSMR Hospital Performance Quintile Rankings for Stroke, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-Only Cohort to the FFS+MA Cohort, CC-Based Variables, CY 2022 | 20 |
| Table 4.1.9: Shifts in RSMR Hospital Performance Quintile Rankings for Stroke, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-only Cohort with CC-Based Variables to the FFS+MA Cohort with Reselected ICD-10-Based Risk Variables, CY 2022..... | 20 |
| Table 4.2.1: Number of Admissions and Observed Complication Rate for THA/TKA, FFS versus MA admissions, CY 2022 | 21 |
| Table 4.2.2: Frequency of CC-Based Risk Variables in the THA/TKA Cohort, FFS versus MA Admissions, CY 2022..... | 21 |
| Table 4.2.3: Frequency of ICD-10-Based Risk Variables in the THA/TKA Cohort, FFS versus MA Admissions, and Adjusted OR and 95% Confidence Intervals for the THA/TKA Hierarchical Logistic Regression Model Using FFS+MA Admissions, CY 2022..... | 23 |
| Table 4.2.4: THA/TKA Complication: Predictive Ability and C-Statistics Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022 | 25 |
| Table 4.2.5: THA/TKA Complication: Hospital Volume, Standardized Complication Ratio (SCR), and Risk-Standardized Complication Rate (RSCR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for All Hospitals | 26 |

| | |
|---|----|
| Table 4.2.6: THA/TKA Complication: Hospital Volume, Standardized Complication Ratio (SCR), and Risk-Standardized Complication Rate (RSCR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions | 26 |
| Table 4.2.7: THA/TKA Complication: Between Hospital Variance and Signal-to-Noise Reliability (STNR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions | 27 |
| Table 4.2.8: Shifts in RSCR Hospital Performance Quintile Rankings for THA/TKA, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-Only Cohort to the FFS+MA Cohort, CC-Based Variables, CY 2022 | 28 |
| Table 4.2.9: Shifts in RSCR Hospital Performance Quintile Rankings for THA/TKA, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-only Cohort with CC-Based variables to the FFS+MA Cohort with Reselected ICD-10-Based Risk Variables, CY 2022..... | 28 |

Center for Outcomes Research and Evaluation Project Team

Medicare Advantage Team:

Kelly Kyanko, MD, MHS – Project Lead
Wanda Johnson, BS, RN – Team Coordinator
Shu-Xia Li, PhD – Analytic Leadership, Associate Director of Data Management and Analytics
Jacqueline Grady, MS – Division Director
Hiral Dudhwala, RN, MSN/MPH – Division Lead
Jennifer Falcone, BA – Project Manager
Elizabeth Triche, PhD – Associate Director, Quality Measurement Programs
Yongfei Wang*, MS – Lead Analyst
Jing Zhang*, MBA, MPhil, MS – Data Manager
Isabella Epshtein, MA – Research Associate
Lisa G. Suter*, MD – Contract Director

Risk Model Respecification Team:

Chenxi Huang*, PhD – Project Lead
Jennifer Falcone, BA – Project Manager
Philippa Chadwick, MPH – Team Coordinator
Zhenqiu Lin, PhD – Analytic Leadership, Senior Director of Data Management and Analytics
Shu-Xia Li, PhD – Analytic Leadership, Associate Director of Data Management and Analytics
Jacqueline Grady, MS – Division Director
Elizabeth Triche, PhD – Associate Director, Quality Measurement Programs
Yongfei Wang*, MS – Lead Analyst
Ji Chen*, PhD – Data Analyst
Peizheng Chen*, MS – Data Analyst
Samantha Mancuso, MPH – Research Associate
Sierra Ottillie-Kovelman, MPH – Research Associate
Lisa G. Suter*, MD – Contract Director

* Yale School of Medicine

Acknowledgements

This work is a collaborative effort, and the authors gratefully acknowledge Jinghong Gao from YNHHS/CORE and Raquel Myers, Vinitha Meyyur, Melissa Hager, Ngozi Uzokwe, Julia Venanzi, Grace Snyder, Traci Archibald, Lang Le and John Green at CMS for their contributions to this work.

NOTE: This supplemental methodology report is not meant to replace the original measure methodology reports, but to provide additional information and results based on the addition of Medicare Advantage (MA) admissions to the cohorts and the modification of the risk adjustment models. The original methodology reports for the measures are available on QualityNet [here](#).

1. EXECUTIVE SUMMARY

In this supplemental methodology report, we present the rationale and testing results of updates to the hospital-level 30-day risk-standardized mortality rates (RSMRs) following stroke and the hospital-level 30-day risk-standardized complication rates (RSCRs) following elective total hip arthroplasty and/or total knee arthroplasty (THA/TKA) admissions. The updates include: 1) integrating Medicare Advantage (MA) beneficiaries into the cohorts and, 2) the reselection of risk adjustment variables. All other specifications remain the same.

For testing purposes, the cohorts include hospital admissions with discharge dates from January 1 to December 30, 2022. Inpatient, outpatient, professional, and DME claims for Medicare Fee-For-Service (FFS) and MA beneficiaries were extracted from the Centers for Medicare & Medicaid Services (CMS) Integrated Data Repository (IDR). The MA claims data comprise Medicare Advantage Organization (MAO)-submitted encounter data (Encounter Data Records and Chart Review Records for all settings) and hospital-submitted inpatient MA claims.¹

The addition of MA admissions into these measures approximately doubled the admissions in the cohorts and led to improved measure reliability and more hospitals and beneficiaries included for measure calculation. Unadjusted 30-day mortality rate was slightly lower for MA versus FFS admissions for stroke mortality measure and unadjusted 30-day complication rate was slightly higher for MA for THA/TKA complication measure. The prevalence of comorbidities was generally higher in the MA cohort as compared to FFS.

A new approach to variable reselection was implemented to leverage the specificity of individual International Classification of Diseases (ICD)-10 codes in place of Condition Categories (CCs) to improve performance of the risk adjustment models. With this new variable selection approach, the discriminative performance of the models as measured by c-statistics, was significantly better for stroke mortality and remained the same for THA/TKA complications. Calibration performance also proved to be satisfactory using the new approach. After the two measure updates, we observed meaningful shifts in hospital performance.

2. BACKGROUND AND OBJECTIVES

2.1. Importance of Including MA Beneficiaries in Hospital Outcome Measures

Including MA beneficiaries in CMS hospital outcome measures helps ensure that hospital quality is measured across all Medicare beneficiaries and not just the FFS population. MA beneficiary enrollment has been rapidly expanding as a share of Medicare beneficiaries. In 2023, nearly 51% of the eligible Medicare beneficiaries — or 30.8 million people — were covered by MA plans.² The Congressional Budget Office projects that by 2030, 62% of beneficiaries will be covered by MA plans.³ Consequently, using FFS-only beneficiaries may exclude a large segment of the focus population for CMS quality measures, which are intended to measure the quality of care of all Medicare beneficiaries.

Inclusion of MA beneficiaries has several important benefits for the reliability and validity of the hospital outcome measures. The addition of MA beneficiaries to FFS significantly increases the size of the measure's cohort, which enhances the reliability of the measure scores, leads to more hospitals receiving results, and increases the chance of identifying meaningful differences in quality for some low-volume hospitals. Moreover, this update addresses stakeholder concerns about differences in quality for MA and FFS beneficiaries.^{4,5} The addition of MA inpatient admissions also allows for inclusion in the measure of beneficiaries who switch between FFS and MA. CMS's current claims-based measures require enrollment in FFS Part A and Part B for the 12 months prior to the date of admission and Part A during the index admission.

2.2. Importance of Risk Adjustment Model Changes

The goal of risk-adjustment models is to adjust for case-mix differences across the hospitals. Risk adjustment supports fair and accurate comparison of outcomes across measured entities by including an adjustment for factors such as age, comorbid diseases, and indicators of patient frailty, which are clinically relevant and have relationships with the outcome.

The original process for clinical risk adjustment for the current measures involved reviewing CCs for clinical relevance and evaluating the CCs for statistical association with the outcome. The CCs are part of CMS's Hierarchical Condition Categories (HCC), and the HCC system groups the ICD-10 diagnosis codes into larger clinically relevant diagnostic categories.^{6,7} Mappings which show the assignment of ICD-10 codes to the CCs are available on [*QualityNet*](#). In pursuing an approach that best leverages the data and analytical advancements since initial measure development, we developed and evaluated a framework to use individual ICD-10 codes for risk adjustment. The main advantage of leveraging ICD-10 codes in place of CCs is the ability to address the clinical heterogeneity found in the broadly defined CCs. Our previous research indicates that the model performance of the mortality measures is significantly improved by using individual codes instead of CCs.⁸ Therefore, this new approach has been applied to both measures in this report.

2.3. Objectives

We had two main objectives: 1) To assess the impact of incorporating MA inpatient admissions into the claims-based stroke mortality and THA/TKA complication measure, and 2) To improve the performance of risk adjustment models for these measures by leveraging the individual ICD-10 codes rather than CCs.

3. METHODS

3.1. Data Sources

For testing of these measure updates, we extracted all claims and beneficiary data for FFS and MA beneficiaries as well as Medicare provider data from the CMS IDR. The condition- and procedure-specific mortality/complication measures use inpatient claims and enrollment data for cohort construction and outcome derivation and use inpatient and outpatient facility, professional, and durable medical equipment (DME) claims data for risk adjustment. We downloaded claims data for index admissions with the claim discharge date from January 1 to December 30, 2022 (calendar year [CY] 2022) as well as historical claims up to 12 months prior to the index admission based on the claim types in [Table 3.1](#). We also downloaded beneficiary information such as birth date, date of death, and enrollment information needed for cohort inclusion and exclusion criteria. We downloaded provider history data that details the association between the CMS Certification Number (CCN) and National Provider Identifier (NPI).

Most MA beneficiary inpatient admissions had two claim submission sources: MAO-submitted encounter claims and hospital-submitted claims. MAO-submitted encounter claims are information-only (i.e., not billing) claims for items and services provided under the plan that are required to be submitted by MAOs to CMS.¹ Hospitals that receive disproportionate-share hospital or medical education payments from Medicare are also required to submit information-only claims for inpatient stays for MA beneficiaries.

To create the combined FFS+MA cohort, we included both MAO-submitted and hospital-submitted MA admission claims. While most hospitals submit MA inpatient claims, not all hospitals are required to submit claims for MA beneficiaries (i.e., those that do not receive disproportionate-share hospital or medical education payments from Medicare), so MAO-submitted claims capture additional admissions not found in the hospital-submitted claims. However, there are benefits in including the hospital-submitted claims. Hospital-submitted claims are timelier than MAO-submitted claims, which is advantageous for reporting deadlines for CMS hospital outcome measures. In addition, a small proportion of admissions were only found in the hospital-submitted claims. Further, unlike MAO-submitted claims which are associated with NPI, hospital-submitted claims are already associated with a CCN used to identify hospitals in the CMS outcome measures. Therefore, if an admission was found in both datasets, we used the claim found in the hospital-submitted data. For a small portion of admissions with only MAO-submitted claims, we obtained the CCN using the IDR provider history data through NPI, claim discharge date, provider history begin (effective) date, and provider history end (obsolete) date. Admissions with only MAO-submitted claims not associated with a CCN were excluded from analyses (<5% of all admissions).

Hospital measures used for public reporting are limited to short-term acute care hospitals and critical access hospitals. In a last step, we used the CCN taxonomy to restrict the claims to those filed by acute care hospitals (3rd and 4th digit as '01') and critical access hospitals (3rd and 4th digit as '13').

Table 3.1: Claim Type Codes

| Type of Claim | FFS | Hospital-submitted MA | MAO-submitted (encounter) MA |
|---------------------|--------|-----------------------|--|
| Inpatient | 60 | 62, 63, 64 | 4011, 4041 |
| Outpatient Facility | 40 | - | 4012 – 4014, 4022, 4023, 4034, 4043, 4071 – 4077, 4079, 4083, 4085, 4089 |
| Professional | 71, 72 | - | 4700 |
| DME | 81, 82 | - | 4800 |

3.2. Cohort and Outcomes

The cohorts included hospital admissions with discharge dates from January 1 to December 30, 2022 (CY 2022). The risk adjustment data were derived from both FFS and MA inpatient and outpatient claims one year prior to and during the index claims. We followed the methodology for the current FFS-only mortality/complication measures for cohort inclusion/exclusion criteria, risk factor derivations from inpatient, outpatient, DME, and professional claims diagnoses/procedures during the 12 months prior to admission or present on admission (POA) at the index hospitalization, outcome definitions, and measure score calculation. After adding the MA beneficiaries, the enrollment requirement was updated to include patients with 12 months FFS or MA enrollment prior to the index admission. Information on the FFS-only measures, including measure specifications and calculation methodology, is available on [QualityNet](#) at:

- 2023 Condition-Specific Mortality Measure Updates and Specifications Report: <https://qualitynet.cms.gov/inpatient/measures > Mortality Measures > Methodology>
- 2023 Procedure-Specific Complication Measure Updates and Specifications Report: <https://qualitynet.cms.gov/inpatient/measures > Complication Measure > Methodology>

3.3. Risk Model Reselection

For candidate risk variables, we included all secondary ICD-10 codes documented as POA during the index admission (with the exception of the palliative care code of Z51.5 which effective October 1, 2021, was considered POA-exempt) and both principal and secondary ICD-10 codes in the 12 months prior to admission from any inpatient, outpatient, professional, and DME provider claims. For procedure-specific measures, we additionally considered the principal discharge diagnosis code for the index admission. We also considered age, frailty, sex, an indicator for whether the admission was MA vs. FFS, and other non-individual-ICD variables in the existing publicly reported CMS mortality measures. The variable selection of individual ICD codes mainly relied on data-driven methodologies involving three key steps: 1) pre-processing, 2) evaluating association with outcome, and 3) consideration of associations between other non-individual-code variables, including frailty, with the outcome.

In pre-processing, we screened and included index and history (pre-index) codes if their prevalence exceeded 0.5% and 2.5%, respectively. Further, pairs of index and pre-index codes that had a correlation larger than 0.8 were combined into one risk variable. Specific ICD-10 codes for social risk factors were removed from the candidate list to be consistent with how the measures currently address social risk. For the stroke mortality measure, we additionally excluded ICD-10 codes that begin with R297 since they are components of the National Institutes of Health Stroke Scale (NIHSS) variable included in the

risk adjustment model for the measure as a numeric variable in a later stage. Finally, pairs of index and pre-index ICD-10 codes where the difference in association with the outcome, measured by Odds Ratio (OR), was less than 0.2 were merged.

In the second step, we included the remaining candidate variables with age in a multivariable logistic regression model and underwent variable selection through 1,000 iterations of bootstrapping. We selected variables which were statistically significantly associated with outcome ($p < 0.05$) greater than a certain cutoff value of frequency over the bootstrapped samples. The cutoff value was chosen for each measure based on empirical evaluation of the model performance. We forced age into the model if it was not selected into the model through the bootstrapping process.

Lastly, based on literature evidence, specific suggestions and guidance from the consensus-based entity for measure endorsement, the Assistant Secretary for Planning and Evaluation, other stakeholders, as well as prior testing results, we included a claims-based indicator of frailty that was developed for CMS' Multiple Chronic Conditions measure⁹ in the final model for all measures. We generally did not include sex as a variable since sex can be considered a socio-demographic variable. There were other non-individual-ICD variables currently included in the publicly reported CMS mortality/complication measures that may contain additional predictive information. Such variables were included in the final models if their regression coefficients were statistically significant when added to the models. We also added into the model for all measures the history of coronavirus disease 2019 (COVID-19) variable to be consistent with current CMS policy. For the stroke mortality measure only, we added into the model the NIHSS score variable derived from ICD-10 codes R29701–R29742 corresponding to NIHSS score 1–42. For patients with no R297 codes, we imputed the NIHSS score as 0.¹⁰

For the combined MA and FFS cohort, the risk adjustment model was updated to include an MA indicator (versus FFS) as a main effect. This was to adjust for the generally higher prevalence of comorbidities in the MA cohort, especially among the pre-index variables that were derived from services in the outpatient setting (e.g., physician visits). For the stroke mortality measure, the NIHSS variable was also included in the final model as specified in the current measure.

3.4. Statistical Analyses

We first compared between MA and FFS admissions the number of admissions and observed (unadjusted) mortality rates for stroke and observed complication rates for THA/TKA. We then examined risk variable prevalence in MA and FFS admissions for both the CC-based (original) and ICD-10-based (reselected) risk variables. For MA+FFS admissions with reselected ICD-10-based variables, we calculated the adjusted OR and 95% confidence intervals (CIs) for the hierarchical logistic regression model.

To evaluate the impact of adding MA admissions and risk variable reselection on model performance metrics, we compared c-statistics and predictive ability for three different combinations of cohorts and risk models: 1) FFS-only admissions with the original CC-based risk model, 2) FFS+MA admissions with the original CC-based risk model, and 3) FFS+MA admissions with reselected ICD-10-based variables. Calibration performance was also assessed by calibration slope and intercept and visually by calibration plots, both in the overall cohort and in subgroups stratified by sex, MA indicator, and hospital volume.

We used hierarchical logistic models with a random effect for hospitals to calculate hospital risk-standardized mortality ratios and rates (SMRs and RSMRs) for stroke, and RSCRs following THA/TKA

admissions and compared these and the number of hospitals using the three different combinations of cohort and risk model variables listed above. We show the distribution of measure scores among all hospitals and among reporting hospitals with at least 25 admissions. We also calculated and compared signal-to-noise reliability (STNR) for hospitals with at least 25 admissions based on between hospital variance and hospital volume. The volume threshold of 25 admissions used here was to align with the public reporting volume cutoff.

To assess the overall impact of adding MA data to hospital measure scores, using original CC-based risk variables we examined shifts in hospital RSMR/RSCR quintiles in the FFS-only cohort versus the combined FFS+MA cohort among hospitals with at least 25 FFS admissions. To examine the associations between hospital characteristics and the addition of MA admissions, we examined quintile shifts in hospital RSMR/RSCR by quintiles of the proportion of hospital MA admissions and by quintiles of overall hospital volume. We then repeated these analyses to assess the impact of adding both MA and updated risk model variables, examining hospital performance shifts in the FFS-only cohort with the original CC-based variables and the FFS+MA cohort with the reselected ICD-10-based variables.

4. RESULTS

4.1. Stroke Mortality Results

Stroke Admission Volume and Observed Mortality Rate

As presented in [Table 4.1.1](#), the FFS+MA cohort included 280,536 unique admissions from January 1 – December 30, 2022 (140,035 FFS and 140,501 MA). The observed (unadjusted) 30-day mortality rate for the FFS+MA cohort for Stroke was 12.9%. The observed mortality rate was 13.5% among FFS beneficiaries compared to 12.2% among MA beneficiaries (difference 1.3%).

Table 4.2.1: Number of Admissions and Observed 30-Day Mortality Rate for Stroke, FFS versus MA Admissions, CY 2022

| Stroke | MA + FFS | FFS | MA | Difference FFS – MA |
|--------------------|----------|---------|---------|---------------------|
| N | 280,536 | 140,035 | 140,501 | NA |
| Mortality Rate (%) | 12.9 | 13.5 | 12.2 | 1.3 |

Frequency of Stroke Risk Variables

We examined the frequencies of variables used for risk adjustment in FFS and MA admissions. The variables from the original CC-based risk model are presented in [Table 4.1.2](#), and the reselected ICD-10-based variables in [Table 4.1.3](#). Frequencies of model variables were generally higher in MA than FFS admissions for both the CC- and ICD-10-based variables. The median difference in risk variable prevalence between FFS and MA (%FFS – %MA) was -0.9% for CC-based variables with a range from -7.7% to 2.6%. The risk variable prevalence differences between FFS and MA for ICD-10-based variables ranged from -8.3% to 3.1% with no difference at the median, however for ICD-10 codes in the 12 months prior to admission (pre-index codes), the differences were more pronounced. [Table 4.1.3](#) also presents adjusted OR and 95% CIs for the hierarchical logistic regression model using FFS+MA admissions.

Table 4.3.2: Frequency of CC-Based Risk Variables in the Stroke Cohort, FFS versus MA Admissions, CY 2022

| Variable (% unless otherwise indicated) | MA + FFS (N= 280,536) | FFS (N= 140,035) | MA (N= 140,501) | FFS - MA |
|--|----------------------------------|-----------------------------|----------------------------|-----------------|
| Age, mean (SD) | 78.7 (8.2) | 79.5 (8.3) | 78.0 (8.0) | 1.5 |
| NIH stroke scale/score, mean (SD) | 4.3 (6.7) | 4.3 (6.7) | 4.3 (6.6) | 0.1 |
| Transfer from another Emergency Department (ED) | 11.0 | 12.0 | 10.0 | 2.0 |
| Metastatic cancer and acute leukemia and other major cancers (CC 8, 9) | 5.6 | 5.8 | 5.4 | 0.4 |
| Protein-calorie malnutrition (CC 21) | 9.1 | 8.9 | 9.3 | -0.4 |
| Other significant endocrine and metabolic disorders (CC 22 – 26) | 93.2 | 92.2 | 94.3 | -2.1 |
| Other gastrointestinal disorders (CC 38) | 55.0 | 53.1 | 56.9 | -3.8 |
| Disorders of the vertebrae and spinal discs (CC 41) | 25.0 | 24.0 | 26.0 | -2.0 |
| Osteoarthritis of hip or knee (CC 42) | 15.4 | 15.0 | 15.7 | -0.7 |
| Other musculoskeletal and connective tissue disorders (CC 45) | 66.5 | 64.9 | 68.0 | -3.2 |
| Iron deficiency and other/unspecified anemia and blood disease (CC 49) | 38.5 | 38.0 | 39.1 | -1.1 |
| Dementia or senility (CC 51 – 53) | 35.1 | 32.7 | 37.4 | -4.7 |
| Multiple sclerosis (CC 77, 81) | 22.7 | 21.4 | 23.9 | -2.5 |
| Seizure disorders and convulsions (CC 79) | 8.0 | 7.6 | 8.5 | -0.9 |
| Congestive heart failure (CC 85) | 34.0 | 32.3 | 35.6 | -3.4 |
| Congenital cardiac/circulatory defects (CC 92,93) | 3.0 | 2.9 | 3.0 | -0.1 |
| Specified heart arrhythmias (CC 96) | 39.6 | 40.9 | 38.3 | 2.6 |
| Cerebral atherosclerosis and aneurysm (CC 102) | 28.7 | 24.8 | 32.5 | -7.7 |
| Pneumonia (CC 114 – 116) | 15.3 | 14.8 | 15.8 | -0.9 |
| Renal failure (CC 135 – 140) | 42.6 | 39.5 | 45.7 | -6.2 |
| History of COVID-19 | 13.5 | 13.7 | 13.3 | 0.4 |

Table 4.4.3: Frequency of ICD-10-Based Risk Variables in the Stroke Cohort, FFS versus MA Admissions, and Adjusted OR and 95% Confidence Intervals for the Stroke Hierarchical Logistic Regression Model Using FFS+MA Admissions, CY 2022

| Variable | Description | MA + FFS (%) (N= 280,536) | FFS (%) (N= 140,035) | MA (%) (N= 140,501) | FFS – MA (%) | FFS + MA OR (95% CI) |
|---|--|------------------------------|-------------------------|------------------------|-----------------|-------------------------|
| AGE | Age, mean (SD) | 78.7 (8.2) | 79.5 (8.3) | 78.0 (8.0) | 1.5 | 1.04 (1.04, 1.04) |
| ICD-10 codes during the index admission | | | | | | |
| A419 | Sepsis, unspecified organism | 1.0 | 1.0 | 1.0 | 0.0 | 1.70 (1.52, 1.89) |
| C1 | End stage renal disease or Dependence on renal dialysis | 1.7 | 1.7 | 1.6 | 0.1 | 1.70 (1.53, 1.90) |
| C787 | Secondary malignant neoplasm of liver and intrahepatic bile duct | 0.7 | 0.7 | 0.6 | 0.1 | 5.96 (5.25, 6.76) |
| C7951 | Secondary malignant neoplasm of bone | 0.7 | 0.8 | 0.7 | 0.1 | 2.23 (1.95, 2.54) |
| D631 | Anemia in chronic kidney disease | 3.1 | 3.1 | 3.1 | -0.1 | 0.84 (0.77, 0.92) |
| E041 | Nontoxic single thyroid nodule | 1.3 | 1.2 | 1.3 | -0.1 | 0.56 (0.47, 0.67) |
| E538 | Deficiency of other specified B group vitamins | 2.1 | 2.1 | 2.1 | 0.0 | 0.70 (0.62, 0.79) |
| E785 | Hyperlipidemia, unspecified | 55.7 | 55.2 | 56.3 | -1.2 | 0.86 (0.83, 0.88) |
| E870 | Hyperosmolality and hypernatremia | 1.7 | 1.6 | 1.7 | -0.1 | 1.59 (1.46, 1.73) |
| E872 | Acidosis | 2.9 | 2.8 | 2.9 | -0.1 | 1.47 (1.37, 1.58) |
| G43909 | Migraine, unspecified, not intractable, without status migrainosus | 1.2 | 1.2 | 1.2 | 0.0 | 0.55 (0.44, 0.68) |
| G8101 | Flaccid hemiplegia affecting right dominant side | 0.8 | 0.8 | 0.8 | 0.0 | 1.96 (1.73, 2.22) |
| G8104 | Flaccid hemiplegia affecting left nondominant side | 0.8 | 0.7 | 0.8 | -0.1 | 1.76 (1.53, 2.01) |
| G8191 | Hemiplegia, unspecified affecting right dominant side | 18.8 | 18.5 | 19.1 | -0.6 | 1.24 (1.18, 1.29) |
| G9340 | Encephalopathy, unspecified | 3.9 | 3.8 | 3.9 | -0.1 | 1.50 (1.40, 1.59) |
| G9341 | Metabolic encephalopathy | 6.9 | 7.0 | 6.8 | 0.2 | 1.36 (1.29, 1.43) |
| G9349 | Other encephalopathy | 3.5 | 3.5 | 3.6 | -0.1 | 1.43 (1.34, 1.53) |
| G935 | Compression of brain | 1.2 | 1.1 | 1.2 | -0.1 | 2.02 (1.81, 2.26) |
| G936 | Cerebral edema | 4.4 | 6.4 | 4.4 | 0.0 | 1.80 (1.69, 1.91) |
| H518 | Other specified disorders of binocular movement | 0.8 | 0.8 | 0.9 | -0.1 | 1.17 (1.03, 1.34) |
| I10 | Essential (primary) hypertension | 54.3 | 54.4 | 54.1 | 0.3 | 0.84 (0.82, 0.87) |
| I214 | Non-ST elevation (NSTEMI) myocardial infarction | 1.4 | 1.4 | 1.5 | -0.1 | 1.94 (1.76, 2.13) |
| I21A1 | Myocardial infarction type 2 | 2.3 | 2.3 | 2.3 | 0.0 | 1.30 (1.20, 1.41) |
| I2699 | Other pulmonary embolism without acute cor pulmonale | 0.7 | 0.7 | 0.7 | 0.0 | 1.61 (1.40, 1.86) |
| I440 | Atrioventricular block, first degree | 1.9 | 2.0 | 1.9 | 0.1 | 0.72 (0.64, 0.82) |

| Variable | Description | MA + FFS (%) (N= 280,536) | FFS (%) (N= 140,035) | MA (%) (N= 140,501) | FFS – MA (%) | FFS + MA OR (95% CI) |
|----------|--|------------------------------|-------------------------|------------------------|-----------------|-------------------------|
| I480 | Paroxysmal atrial fibrillation | 12.1 | 13.0 | 11.3 | 1.7 | 0.87 (0.83, 0.91) |
| I4821 | Permanent atrial fibrillation | 1.6 | 1.7 | 1.4 | 0.3 | 0.84 (0.75, 0.93) |
| I4892 | Unspecified atrial flutter | 2.3 | 2.4 | 2.2 | 0.2 | 0.83 (0.75, 0.91) |
| I5022 | Chronic systolic (congestive) heart failure | 4.1 | 4.0 | 4.2 | -0.2 | 0.98 (0.91, 1.05) |
| I5032 | Chronic diastolic (congestive) heart failure | 6.1 | 6.3 | 5.9 | 0.4 | 0.89 (0.84, 0.95) |
| I609 | Nontraumatic subarachnoid hemorrhage, unspecified | 0.5 | 0.5 | 0.5 | 0.0 | 1.86 (1.59, 2.17) |
| I671 | Cerebral aneurysm, nonruptured | 1.8 | 1.8 | 1.9 | -0.2 | 0.82 (0.72, 0.92) |
| I951 | Orthostatic hypotension | 1.1 | 1.1 | 1.0 | 0.1 | 0.71 (0.60, 0.85) |
| J189 | Pneumonia, unspecified organism | 1.9 | 1.9 | 1.8 | 0.1 | 1.56 (1.43, 1.70) |
| J690 | Pneumonitis due to inhalation of food and vomit | 2.3 | 2.4 | 2.2 | 0.2 | 1.76 (1.63, 1.89) |
| J90 | Pleural effusion, not elsewhere classified | 1.0 | 1.1 | 0.9 | 0.2 | 1.40 (1.25, 1.56) |
| J9600 | Acute respiratory failure, unspecified whether with hypoxia or hypercapnia | 0.7 | 0.7 | 0.8 | -0.1 | 3.44 (3.04, 3.89) |
| J9601 | Acute respiratory failure with hypoxia | 3.9 | 3.8 | 4.0 | -0.2 | 2.35 (2.21, 2.49) |
| K7460 | Unspecified cirrhosis of liver | 0.6 | 0.5 | 0.6 | 0.0 | 1.62 (1.37, 1.92) |
| N170 | Acute kidney failure with tubular necrosis | 0.7 | 0.6 | 0.7 | -0.1 | 1.79 (1.56, 2.06) |
| Q211 | Atrial septal defect | 2.0 | 2.0 | 2.0 | 0.0 | 0.72 (0.64, 0.83) |
| R1310 | Dysphagia, unspecified | 10.0 | 10.1 | 9.9 | 0.2 | 1.23 (1.18, 1.29) |
| R260 | Ataxic gait | 0.8 | 0.9 | 0.8 | 0.1 | 0.53 (0.40, 0.70) |
| R2681 | Unsteadiness on feet | 1.2 | 1.2 | 1.1 | 0.1 | 0.70 (0.57, 0.86) |
| R2689 | Other abnormalities of gait and mobility | 1.2 | 1.2 | 1.2 | 0.1 | 0.69 (0.57, 0.83) |
| R270 | Ataxia, unspecified | 3.8 | 3.7 | 3.9 | -0.2 | 0.70 (0.62, 0.78) |
| R413 | Other amnesia | 0.5 | 0.5 | 0.5 | 0.1 | 0.49 (0.36, 0.67) |
| R4189 | Other symptoms and signs involving cognitive functions and awareness | 0.8 | 0.8 | 0.8 | 0.1 | 0.64 (0.53, 0.77) |
| R42 | Dizziness and giddiness | 1.7 | 1.7 | 1.7 | 0.0 | 0.57 (0.47, 0.69) |
| R4701 | Aphasia | 25.2 | 25.6 | 24.9 | 0.8 | 1.07 (1.03, 1.12) |
| R627 | Adult failure to thrive | 1.3 | 1.3 | 1.3 | 0.0 | 1.44 (1.31, 1.59) |
| R64 | Cachexia | 1.0 | 1.0 | 1.0 | 0.1 | 1.51 (1.35, 1.69) |
| R7303 | Prediabetes | 3.1 | 2.9 | 3.3 | -0.4 | 0.62 (0.56, 0.70) |
| R778 | Other specified abnormalities of plasma proteins | 2.3 | 2.3 | 2.2 | 0.1 | 1.24 (1.13, 1.36) |
| R911 | Solitary pulmonary nodule | 1.0 | 1.0 | 1.0 | 0.0 | 0.74 (0.63, 0.89) |

| Variable | Description | MA + FFS (%) (N= 280,536) | FFS (%) (N= 140,035) | MA (%) (N= 140,501) | FFS – MA (%) | FFS + MA OR (95% CI) |
|--|--|------------------------------|-------------------------|------------------------|-----------------|-------------------------|
| Z20822 | Contact with and (suspected) exposure to COVID-19 | 50.9 | 51.3 | 50.6 | 0.7 | 0.75 (0.73, 0.78) |
| Z515 | Encounter for palliative care | 9.4 | 10.1 | 8.8 | 1.3 | 21.75 (20.94, 22.59) |
| Z66 | Do not resuscitate | 15.8 | 147.4 | 14.3 | 3.1 | 1.89 (1.82, 1.96) |
| Z7401 | Bed confinement status | 1.1 | 1.1 | 1.1 | 0.0 | 1.25 (1.12, 1.39) |
| Z751 | Person awaiting admission to adequate facility elsewhere | 0.5 | 0.4 | 0.7 | -0.3 | 0.33 (0.25, 0.44) |
| Z7901 | Long term (current) use of anticoagulants | 16.2 | 17.0 | 15.5 | 1.5 | 0.93 (0.89, 0.97) |
| Z7902 | Long term (current) use of antithrombotics/antiplatelets | 13.0 | 12.7 | 13.4 | -0.7 | 0.83 (0.78, 0.87) |
| Z7982 | Long term (current) use of aspirin | 33.9 | 33.9 | 33.9 | 0.0 | 0.75 (0.73, 0.78) |
| Z7984 | Long term (current) use of oral hypoglycemic drugs | 13.3 | 12.0 | 14.6 | -2.6 | 0.86 (0.81, 0.91) |
| Z79890 | Hormone replacement therapy | 6.3 | 6.8 | 5.7 | 1.1 | 0.81 (0.76, 0.88) |
| Z79899 | Other long term (current) drug therapy | 29.2 | 29.9 | 28.5 | 1.4 | 0.85 (0.81, 0.88) |
| Z8673 | Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits | 16.6 | 16.6 | 16.6 | 0.0 | 0.89 (0.85, 0.93) |
| Z87891 | Personal history of nicotine dependence | 22.4 | 23.1 | 21.8 | 1.3 | 0.93 (0.90, 0.97) |
| ICD-10 codes in the 12 months prior to admission | | | | | | |
| G459 | Transient cerebral ischemic attack, unspecified | 16.0 | 15.5 | 16.4 | -0.9 | 0.78 (0.75, 0.82) |
| I63511 | Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery | 6.6 | 6.2 | 7.0 | -0.8 | 1.23 (1.16, 1.30) |
| I63512 | Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery | 7.4 | 7.0 | 7.8 | -0.8 | 1.26 (1.20, 1.33) |
| I6381 | Other cerebral infarction due to occlusion or stenosis of small artery | 6.3 | 5.7 | 6.8 | -1.1 | 0.78 (0.72, 0.84) |
| I6521 | Occlusion and stenosis of right carotid artery | 6.2 | 5.5 | 6.8 | -1.2 | 1.13 (1.07, 1.21) |
| J90 | Pleural effusion, not elsewhere classified | 8.2 | 7.8 | 8.7 | -0.8 | 1.26 (1.20, 1.32) |
| M1711 | Unilateral primary osteoarthritis, right knee | 4.7 | 4.7 | 4.7 | -0.1 | 0.81 (0.75, 0.88) |
| R202 | Paresthesia of skin | 4.8 | 3.6 | 6.0 | -2.4 | 0.85 (0.77, 0.94) |
| R29818 | Other symptoms and signs involving the nervous system | 23.1 | 21.4 | 24.7 | -3.2 | 0.88 (0.85, 0.92) |
| R4182 | Altered mental status, unspecified | 24.9 | 23.6 | 26.2 | -2.5 | 1.21 (1.17, 1.25) |
| R4701 | Aphasia | 10.4 | 8.9 | 11.9 | -3.1 | 0.87 (0.83, 0.92) |
| R634 | Abnormal weight loss | 3.8 | 3.3 | 4.3 | -1.0 | 1.30 (1.22, 1.40) |
| R778 | Other specified abnormalities of plasma proteins | 5.3 | 3.7 | 6.9 | -3.1 | 1.26 (1.19, 1.34) |

| Variable | Description | MA + FFS (%) (N= 280,536) | FFS (%) (N= 140,035) | MA (%) (N= 140,501) | FFS – MA (%) | FFS + MA OR (95% CI) |
|--|--|------------------------------|-------------------------|------------------------|-----------------|-------------------------|
| Z1231 | Encounter for screening mammogram for malignant neoplasm of breast | 11.9 | 11.5 | 12.2 | -0.7 | 0.75 (0.71, 0.79) |
| Z4682 | Encounter for fitting and adjustment of non-vascular catheter | 3.7 | 3.4 | 3.9 | -0.5 | 1.33 (1.24, 1.42) |
| Z66 | Do not resuscitate | 6.4 | 7.1 | 5.8 | 1.4 | 1.16 (1.10, 1.23) |
| ICD-10 codes either during the index admission or 12 months prior to admission | | | | | | |
| D696 | Thrombocytopenia, unspecified | 6.0 | 5.9 | 6.2 | -0.3 | 1.30 (1.22, 1.40) |
| D72829 | Elevated white blood cell count, unspecified | 8.4 | 7.8 | 9.1 | -1.3 | 1.26 (1.19, 1.34) |
| E119 | Type 2 diabetes mellitus without complications | 36.1 | 32.0 | 40.3 | -8.3 | 0.75 (0.71, 0.79) |
| F0390 | Unspecified dementia without behavioral disturbance | 14.6 | 14.5 | 14.8 | -0.3 | 1.33 (1.24, 1.42) |
| G8194 | Hemiplegia, unspecified affecting left nondominant side | 21.8 | 21.3 | 22.3 | -1.0 | 1.16 (1.10, 1.23) |
| I4891 | Unspecified atrial fibrillation | 26.9 | 26.9 | 26.9 | 0.1 | 1.30 (1.22, 1.40) |
| R000 | Tachycardia, unspecified | 6.6 | 6.0 | 7.1 | -1.1 | 1.14 (1.08, 1.21) |
| R200 | Anesthesia of skin | 7.4 | 6.1 | 8.7 | -2.6 | 0.69 (0.63, 0.75) |
| R471 | Dysarthria and anarthria | 21.5 | 20.5 | 22.6 | -2.1 | 0.89 (0.85, 0.92) |
| R4781 | Slurred speech | 17.9 | 16.8 | 18.9 | -2.0 | 0.89 (0.85, 0.93) |
| Other risk variables | | | | | | |
| MCCFI | Multiple Chronic Conditions Frailty Index | 26.0 | 25.5 | 26.5 | -1.0 | 1.28 (1.23, 1.32) |
| NIHSS | NIHSS mean (SD) | 4.3 (6.7) | 4.3 (6.6) | 4.3 (6.7) | 0.3 | 1.04 (1.04, 1.04) |
| HX_COVID | History of COVID-19 | 13.5 | 13.7 | 13.3 | 0.4 | 0.89 (0.85, 0.93) |
| MA | MA (versus FFS) | 50.1 | NA | NA | NA | 0.95 (0.92, 0.98) |

Stroke Model Performance

Table 4.1.4 presents model performance for the Stroke measure across three scenarios: the FFS-only cohort with CC-based risk variables, the FFS+MA cohort with CC-based risk variables, and the FFS+MA cohort with ICD-10-based risk variables. Predictive ability and c-statistics were similar between the FFS-only and FFS+MA cohorts using the original CC-based variables. For the MA+FFS cohort, the model using reselected ICD-10-based risk variables had a higher c-statistic compared to the original CC-based model and wider predictive ability. Calibration performance was generally acceptable across all modeling approaches in the overall cohort and in subgroups, including male versus female, MA versus FFS, and quartiles of hospital volume (figures not shown).

Table 4.5.4: Stroke Mortality: Predictive Ability and C-Statistics Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022

| Value | FFS-only cohort with CC-based risk variables | FFS+MA cohort with CC-based risk variables | FFS+MA cohort with ICD-10-based risk variables |
|--|--|--|--|
| Predictive Ability, % (lowest decile – highest decile) | 1.8 – 47.8 | 1.7 – 45.8 | 0.5 – 75.2 |
| c-statistic | 0.79 | 0.79 | 0.91 |

Note: These statistics were calculated using the patient-level logistic model.

Risk-Standardized Mortality Rates for Stroke

Tables 4.1.5 and 4.1.6 present distribution of hospital volume, SMR, and RSMR for all hospitals (Table 4.1.5) and for hospitals with 25 or more eligible admissions (Table 4.1.6). Numbers of hospitals and admissions were higher in the combined FFS+MA data compared to the FFS-only data. With the addition of MA data, 147 additional hospitals were included in the measure (3,830 versus 3,683) and 491 additional hospitals met the 25 or more admissions cutoff for public reporting (2,033 versus 1,542). For all hospitals, the mean RSMR was 13.6% for the FFS-only cohort with CC-based risk variables, 12.9% for the FFS+MA cohort with CC-based risk variables, and 13.2% for the FFS+MA cohort with reselected ICD-10-based risk variables. Among hospitals with 25 or more admissions, mean RSMRs were 13.5%, 12.8%, and 13.0%, respectively.

Table 4.6.5: Stroke Mortality: Hospital Volume, Standardized Mortality Ratio (SMR), and Risk-Standardized Mortality Rate (RSMR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for All Hospitals

| Value | FFS-Only cohort with CC-based risk variables (N= 3,683 hospitals) | | FFS+MA cohort with CC-based risk variables (N= 3,830 hospitals) | | FFS+MA cohort with ICD-10-based risk variables (N= 3,830 hospitals) | |
|------------------------|--|----------------------------|--|----------------------------|--|----------------------------|
| | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) |
| Hospital Volume | 38.0 (52.6) | 16 (4, 51) | 73.2 (102.2) | 30 (6, 101) | 73.25 (102.2) | 30 (6, 101) |
| SMR | 1.00 (0.08) | 1.00 (0.96, 1.05) | 1.01 (0.10) | 1.00 (0.96, 1.06) | 1.03 (0.16) | 0.99 (0.94, 1.09) |
| RSMR (%) | 13.6 (1.1) | 13.5 (13.1, 14.1) | 12.9 (1.3) | 12.8 (12.3, 13.6) | 13.2 (2.1) | 12.8 (12.1, 14.1) |

Table 4.7.6: Stroke Mortality: Hospital Volume, Standardized Mortality Ratio (SMR), and Risk-Standardized Mortality Rate (RSMR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions

| Value | FFS-Only cohort with CC-based risk variables (N= 1,542 hospitals) | | FFS+MA cohort with CC-based risk variables (N= 2,033 hospitals) | | FFS+MA cohort with ICD-10-based risk variables (N= 2,033 hospitals) | |
|------------------------|--|----------------------------|--|----------------------------|--|----------------------------|
| | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) |
| Hospital Volume | 80.6 (58.4) | 61 (39, 105) | 131.3 (111.5) | 95 (54, 174) | 131.3 (111.5) | 95 (54, 174) |
| SMR | 1.00 (0.11) | 0.99 (0.92, 1.06) | 1.00 (0.13) | 0.99 (0.91, 1.07) | 1.01 (0.18) | 0.98 (0.90, 1.08) |
| RSMR (%) | 13.5 (1.4) | 13.4 (12.5, 14.3) | 12.8 (1.6) | 12.7 (11.7, 13.7) | 13.0 (2.3) | 12.6 (11.5, 13.9) |

Measure Reliability for Stroke

Between hospital variance and STNR for the measure score comparing the addition of MA admissions to the FFS-only cohort and reselected ICD-10-based variables to the CC-based variables in the FFS+MA cohort are noted in [Table 4.1.7](#). Median STNR, calculated based on between hospital variance and hospital volume, was 0.570 for the FFS-only cohort with CC-based risk variables, 0.684 for the FFS+MA cohort with CC-based risk variables, and 0.852 for the FFS+MA cohort with reselected ICD-10-based risk variables.

Table 4.8.7: Stroke Mortality: Between Hospital Variance and Signal-to-Noise Reliability (STNR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions

| Value | FFS-only cohort with CC-based risk variables | FFS+MA cohort with CC-based risk variables | FFS+MA cohort with ICD-10-based risk variables |
|---------------------------|--|--|--|
| Number of Hospitals | 1,542 | 2,033 | 2,033 |
| Between Hospital Variance | 0.071 | 0.075 | 0.199 |
| STNR: Median (Q1, Q3) | 0.570 (0.458, 0.695) | 0.684 (0.552, 0.799) | 0.852 (0.766, 0.913) |

Change in Hospital Performance for Stroke

Table 4.1.8 shows the quintile shifts in RSMR across hospitals with at least 25 FFS admissions for the Stroke measure in the combined FFS+MA cohort as compared to the FFS-only cohort in hospitals for the model with the original CC-based variables. After adding MA admissions to the FFS-only cohort, about half (49.6%) of hospitals remained in the same performance quintile, and 88.5% remained within +/- 1 quintile. Correlation between hospital RSMRs was 0.82. As hospitals' proportion of MA admissions increased, fewer hospitals remained in the same performance quintile (58.1% among hospitals in the lowest quintile of percent MA admissions; 41.6% of hospitals in the highest quintile of percent of MA admissions). As hospital volume increased, there was not a notable trend in RSMR shifts.

Table 4.1.9 shows the quintile shifts in RSMR across hospitals with at least 25 FFS admissions for the Stroke measure after both measure updates, comparing the combined FFS+MA cohort using the reselected ICD-10-based risk variables to the FFS-only cohort using the CC-based variables. With the addition of the MA admissions and the ICD-10-based risk variables, 34.4% of hospitals remained in the same performance quintile and 71.7% remained within +/- 1 quintile. Correlation between hospital RSMRs was 0.52. There was not a notable trend by proportion of MA admissions or admission volume.

Table 4.9.8: Shifts in RSMR Hospital Performance Quintile Rankings for Stroke, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-Only Cohort to the FFS+MA Cohort, CC-Based Variables, CY 2022

| Description | Same quintile (%) | ±1 quintile (%) | Correlation |
|-----------------------------|-------------------|-----------------|-------------|
| Overall | 49.6 | 88.5 | 0.82 |
| By Percent of MA Admissions | | | |
| Q1: 0.0% – 34.2% | 58.1 | 97.1 | 0.92 |
| Q2: 34.2% – 43.6% | 52.8 | 90.0 | 0.87 |
| Q3: 43.7% – 51.0% | 49.7 | 89.3 | 0.83 |
| Q4: 51.1% – 58.9% | 46.0 | 87.4 | 0.79 |
| Q5: 58.9% – 89.0% | 41.6 | 78.9 | 0.68 |
| By MA+FFS Admission Volume | | | |
| Q1: 28 – 69 admissions | 52.8 | 93.1 | 0.87 |
| Q2: 70 – 101 admissions | 47.9 | 89.9 | 0.80 |
| Q3: 102 – 147 admissions | 48.3 | 87.1 | 0.77 |
| Q4: 148 – 231 admissions | 45.2 | 84.8 | 0.80 |
| Q5: 232 – 1,118 admissions | 53.9 | 87.7 | 0.86 |

Note: Quintile percentages represent the percent of hospitals that stayed in their same (1st column) or within one (2nd column) performance quintile ranking after the addition of MA admissions.

Total N=1,542, representing hospitals with 25 or more FFS admissions

Table 4.10.9: Shifts in RSMR Hospital Performance Quintile Rankings for Stroke, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-only Cohort with CC-Based Variables to the FFS+MA Cohort with Reselected ICD-10-Based Risk Variables, CY 2022

| Description | Same quintile (%) | ±1 quintile (%) | Correlation |
|-----------------------------|-------------------|-----------------|-------------|
| Overall | 34.4 | 71.7 | 0.52 |
| By Percent of MA Admissions | | | |
| Q1: 0.0% – 34.2% | 34.7 | 76.9 | 0.56 |
| Q2: 34.2% – 43.6% | 37.9 | 71.5 | 0.56 |
| Q3: 43.7% – 51.0% | 37.7 | 70.1 | 0.50 |
| Q4: 51.1% – 58.9% | 34.6 | 71.2 | 0.50 |
| Q5: 58.9% – 89.0% | 27.3 | 68.5 | 0.46 |
| By MA+FFS Admission Volume | | | |
| Q1: 28 – 69 admissions | 38.4 | 79.0 | 0.58 |
| Q2: 70 – 101 admissions | 31.5 | 72.2 | 0.53 |
| Q3: 102 – 147 admissions | 31.8 | 69.2 | 0.48 |
| Q4: 148 – 231 admissions | 31.3 | 68.7 | 0.48 |
| Q5: 232 – 1,118 admissions | 39.3 | 69.2 | 0.57 |

Note: Quintile percentages represent the percent of hospitals that stayed in their same (1st column) or within one (2nd column) performance quintile ranking after the addition of MA admissions and with reselected ICD-10-based risk variables.

Total N=1,542, representing hospitals with 25 or more FFS admissions

4.2. Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) Complication Results

THA/TKA Admission Volume and Observed Complication Rate

As presented in [Table 4.2.1](#), the FFS+MA cohort included 147,065 unique admissions from January 1 – December 30, 2022 (93,365 FFS and 53,700 MA). The observed (unadjusted) complication rate for the FFS+MA cohort for THA/TKA was 3.4%. The observed complication rate was 3.2% among FFS beneficiaries compared to 3.7% among MA beneficiaries (difference -0.5%).

Table 4.2.1: Number of Admissions and Observed Complication Rate for THA/TKA, FFS versus MA admissions, CY 2022

| THA/TKA | MA + FFS | FFS | MA | Difference FFS - MA |
|-----------------------|----------|--------|--------|---------------------|
| N | 147,065 | 93,365 | 53,700 | NA |
| Complication Rate (%) | 3.4 | 3.2 | 3.7 | -0.5 |

Frequency of THA/TKA Risk Variables

We examined the frequencies of variables used for risk adjustment in FFS and MA admissions. The variables from the original CC-based risk model are presented in [Table 4.2.2](#), and the reselected ICD-10-based variables in [Table 4.2.3](#). Frequencies of model variables were generally higher in MA than FFS admissions for both the CC- and ICD-10-based variables. The median difference in risk variable prevalence between FFS and MA (%FFS – %MA) was -0.7% for CC-based variables with a range from -12.5% to 1.9%. There was less of a difference overall in risk variable prevalence between FFS and MA for ICD-10-based variables with a median difference of -0.2% (range from -5.6% to 2.9%), however, for ICD-10 codes in the 12 months prior to admission (pre-index codes), the differences were more pronounced. [Table 4.2.3](#) also presents adjusted OR and 95% CIs for the hierarchical logistic regression model using FFS+MA admissions.

Table 4.2.2: Frequency of CC-Based Risk Variables in the THA/TKA Cohort, FFS versus MA Admissions, CY 2022

| Variable (% unless otherwise indicated) | MA + FFS (N= 147,065) | FFS (N= 93,365) | MA (N= 53,700) | FFS - MA |
|--|-----------------------|-----------------|----------------|----------|
| Age, mean (SD) | 74.8 (6.1) | 75.0 (6.1) | 74.6 (6.1) | 0.4 |
| Male | 34.3 | 35.0 | 33.1 | 1.9 |
| Elective THA procedure | 37.0 | 36.9 | 37.2 | -0.4 |
| Number of procedures (two vs. one) | 2.1 | 2.0 | 2.1 | -0.1 |
| Metastatic cancer or acute leukemia (CC 8) | 1.0 | 1.0 | 1.0 | 0.0 |
| Other major cancers (CC 9 – 12) | 13.8 | 14.3 | 12.9 | 1.3 |
| Respiratory/heart/digestive/urinary/other neoplasms (CC 13 – 15) | 19.9 | 20.1 | 19.7 | 0.4 |
| Diabetes mellitus (DM) or DM complications (CC 17 – 19, 122 – 123) | 32.9 | 29.8 | 38.3 | -8.5 |

| Variable (% unless otherwise indicated) | MA + FFS (N= 147,065) | FFS (N= 93,365) | MA (N= 53,700) | FFS - MA |
|--|----------------------------------|----------------------------|---------------------------|-----------------|
| Protein-calorie malnutrition (CC 21) | 1.4 | 1.2 | 1.7 | -0.5 |
| Bone/joint/muscle infections/necrosis (CC 39) | 4.5 | 4.1 | 5.2 | -1.1 |
| Rheumatoid arthritis and inflammatory connective tissue disease (CC 40) | 13.1 | 11.9 | 15.1 | -3.2 |
| Osteoarthritis of hip or knee (CC 42) | 99.8 | 99.8 | 99.8 | 0.0 |
| Osteoporosis and other bone/cartilage disorders (CC 43) | 30.7 | 28.8 | 34.0 | -5.2 |
| Dementia or other specified brain disorders (CC 51 – 53) | 7.1 | 6.3 | 8.6 | -2.2 |
| Major psychiatric disorders (CC 57 – 59) | 12.7 | 9.1 | 18.9 | -9.8 |
| Hemiplegia, paraplegia, paralysis, functional disability (CC 70 – 74, 103 – 104, 189 – 190) | 2.9 | 2.5 | 3.7 | -1.2 |
| Cardio-respiratory failure and shock (CC 84), plus ICD-10-CM codes R09.01 and R09.02 | 5.7 | 5.2 | 6.7 | -1.6 |
| Coronary atherosclerosis or angina (CC 88 – 89) | 28.4 | 28.0 | 29.1 | -1.0 |
| Stroke (CC 99 – 100) | 3.0 | 2.8 | 3.3 | -0.6 |
| Vascular or circulatory disease (CC 106 – 109) | 34.4 | 29.8 | 42.3 | -12.5 |
| Chronic obstructive pulmonary disease (COPD) (CC 111) | 14.5 | 12.5 | 17.9 | -5.4 |
| Pneumonia (CC 114 – 116) | 4.4 | 4.1 | 4.8 | -0.8 |
| Pleural effusion/pneumothorax (CC 117) | 2.1 | 1.9 | 2.4 | -0.5 |
| Dialysis status (CC 134) | 0.4 | 0.4 | 0.5 | -0.1 |
| Renal failure (CC 135 – 140) | 24.3 | 21.6 | 29.1 | -7.5 |
| Decubitus ulcer or chronic skin ulcer (CC 157 – 161) | 3.1 | 3.1 | 3.2 | -0.1 |
| Trauma (CC 166 – 168, 170 – 173) | 7.1 | 6.6 | 7.9 | -1.3 |
| Vertebral fractures without spinal cord injury (CC 169) | 1.5 | 1.5 | 1.6 | -0.1 |
| Other injuries (CC 174) | 27.2 | 26.9 | 27.9 | -1.0 |
| Major complications of medical care and trauma (CC 176 – 177) | 6.4 | 6.3 | 6.6 | -0.3 |
| Morbid obesity (CC 22) | 15.8 | 13.0 | 20.7 | -7.7 |
| Skeletal deformities (ICD-9 code 755.63, ICD – 10 code Q65.89, Q65.9 – CC 204) | 2.6 | 1.0 | 5.4 | -4.4 |
| Post traumatic osteoarthritis (ICD-9 codes 716.15, 716.16, ICD-10 code M12.551, M12.552, M12.559 – CC 205) | 1.7 | 1.6 | 1.9 | -0.2 |
| History of COVID-19 | 13.8 | 14.3 | 13.1 | 1.2 |

Table 4.2.3: Frequency of ICD-10-Based Risk Variables in the THA/TKA Cohort, FFS versus MA Admissions, and Adjusted OR and 95% Confidence Intervals for the THA/TKA Hierarchical Logistic Regression Model Using FFS+MA Admissions, CY 2022

| Variable | Description | MA + FFS (%) (N= 147,065) | FFS (%) (N= 93,365) | MA (%) (N= 53,700) | FFS - MA (%) | FFS + MA OR (95% CI) |
|--|--|------------------------------|------------------------|-----------------------|-----------------|-------------------------|
| AGE | Age, mean (SD) | 74.8 (6.1) | 75.0 (6.1) | 74.6 (6.1) | 0.4 | 1.02 (1.02, 1.03) |
| ICD-10 codes during the index admission | | | | | | |
| D631 | Anemia in chronic kidney disease | 1.1 | 1.0 | 1.3 | -0.3 | 1.71 (1.42, 2.06) |
| D638 | Anemia in other chronic diseases classified elsewhere | 0.6 | 0.5 | 0.7 | -0.1 | 1.91 (1.49, 2.46) |
| E7800 | Pure hypercholesterolemia, unspecified | 14.0 | 14.5 | 13.0 | 1.5 | 0.87 (0.79, 0.95) |
| E8342 | Hypomagnesemia | 0.6 | 0.6 | 0.7 | -0.1 | 1.56 (1.20, 2.03) |
| F0390 | Unspecified dementia without behavioral disturbance | 1.1 | 1.1 | 1.1 | -0.1 | 1.41 (1.14, 1.73) |
| I130 | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | 2.4 | 2.3 | 2.8 | -0.5 | 1.50 (1.31, 1.71) |
| I255 | Ischemic cardiomyopathy | 0.6 | 0.6 | 0.7 | -0.1 | 1.61 (1.27, 2.05) |
| I2720 | Pulmonary hypertension, unspecified | 1.5 | 1.4 | 1.5 | -0.1 | 1.59 (1.35, 1.88) |
| I428 | Other cardiomyopathies | 0.5 | 0.5 | 0.6 | -0.1 | 1.19 (0.88, 1.61) |
| I4820 | Chronic atrial fibrillation, unspecified | 1.5 | 1.5 | 1.4 | 0.1 | 1.36 (1.14, 1.63) |
| I509 | Heart failure, unspecified | 2.1 | 2.1 | 2.3 | -0.2 | 0.77 (0.64, 0.91) |
| J439 | Emphysema, unspecified | 0.9 | 0.8 | 1.1 | -0.3 | 1.45 (1.17, 1.80) |
| N179 | Acute kidney failure, unspecified | 1.8 | 1.6 | 2.1 | -0.5 | 1.58 (1.35, 1.83) |
| Z6842 | Body mass index [BMI] 45.0-49.9, adult | 1.4 | 1.3 | 1.5 | -0.1 | 1.47 (1.20, 1.81) |
| Z803 | Family history of malignant neoplasm of breast | 0.8 | 0.8 | 0.7 | 0.1 | 0.42 (0.25, 0.69) |
| Z853 | Personal history of malignant neoplasm of breast | 4.9 | 5.2 | 4.2 | 1.0 | 0.84 (0.73, 0.97) |
| ICD-10 codes in the 12 months prior to admission | | | | | | |
| E785 | Hyperlipidemia, unspecified | 48.9 | 43.9 | 57.5 | -13.6 | 0.90 (0.85, 0.96) |
| F419 | Anxiety disorder, unspecified | 11.5 | 10.6 | 13.0 | -2.4 | 1.14 (1.05, 1.24) |
| I10 | Essential (primary) hypertension | 75.4 | 72.4 | 80.6 | -8.1 | 1.16 (1.07, 1.25) |
| L820 | Inflamed seborrheic keratosis | 7.5 | 8.8 | 5.3 | 3.6 | 0.78 (0.69, 0.88) |
| M9901 | Segmental and somatic dysfunction of cervical region | 3.4 | 3.6 | 3.0 | 0.6 | 0.80 (0.67, 0.96) |
| S0990XA | Unspecified injury of head, initial encounter | 3.2 | 3.1 | 3.4 | -0.4 | 1.30 (1.14, 1.48) |

| Variable | Description | MA + FFS (%) (N= 147,065) | FFS (%) (N= 93,365) | MA (%) (N= 53,700) | FFS - MA (%) | FFS + MA OR (95% CI) |
|--|---|------------------------------|------------------------|-----------------------|-----------------|-------------------------|
| Z79891 | Long term (current) use of opiate analgesic | 3.6 | 3.1 | 4.5 | -1.4 | 1.31 (1.16, 1.48) |
| ICD-10 codes either during the index admission or 12 months prior to admission | | | | | | |
| E669 | Obesity, unspecified | 26.9 | 25.5 | 29.3 | -3.7 | 1.13 (1.06, 1.21) |
| E871 | Hypo-osmolality and hyponatremia | 6.4 | 6.5 | 6.4 | 0.1 | 1.29 (1.17, 1.42) |
| F32A | Depression, unspecified | 15.0 | 14.5 | 15.8 | -1.3 | 1.27 (1.17, 1.37) |
| I110 | Hypertensive heart disease with heart failure | 8.1 | 6.9 | 10.2 | -3.3 | 1.30 (1.18, 1.42) |
| I2510 | Atherosclerotic heart disease of native coronary artery without angina pectoris | 25.3 | 25.4 | 25.3 | 0.1 | 1.20 (1.12, 1.28) |
| I739 | Peripheral vascular disease, unspecified | 8.3 | 6.3 | 11.9 | -5.6 | 1.23 (1.13, 1.35) |
| J449 | Chronic obstructive pulmonary disease, unspecified | 12.5 | 10.8 | 15.5 | -4.7 | 1.27 (1.17, 1.37) |
| M1611 | Unilateral primary osteoarthritis, right hip | 25.5 | 25.2 | 26.1 | -1.0 | 0.94 (0.86, 1.04) |
| M1612 | Unilateral primary osteoarthritis, left hip | 15.6 | 15.9 | 14.9 | 1.0 | 0.95 (0.86, 1.04) |
| M1711 | Unilateral primary osteoarthritis, right knee | 45.9 | 45.4 | 46.8 | -1.4 | 0.99 (0.92, 1.07) |
| M1712 | Unilateral primary osteoarthritis, left knee | 42.7 | 42.3 | 43.4 | -1.1 | 0.99 (0.92, 1.06) |
| M1990 | Unspecified osteoarthritis, unspecified site | 16.6 | 14.6 | 20.0 | -5.4 | 1.10 (1.03, 1.19) |
| Z6841 | Body mass index [BMI] 40.0 – 44.9, adult | 7.7 | 6.6 | 9.6 | -3.0 | 1.35 (1.23, 1.49) |
| Z794 | Long term (current) use of insulin | 6.5 | 5.7 | 8.1 | -2.4 | 1.18 (1.06, 1.30) |
| Z9181 | History of falling | 4.7 | 4.2 | 5.4 | -1.2 | 1.17 (1.05, 1.31) |
| Other risk variables | | | | | | |
| MCCFI | Multiple Chronic Conditions Frailty Index | 22.0 | 20.7 | 24.4 | -3.7 | 1.16 (1.08, 1.24) |
| PROC_THA | Elective THA procedure | 37.0 | 36.9 | 37.2 | -0.4 | 1.83 (1.62, 2.07) |
| TWOPROC | Number of procedures (two vs. one) | 2.1 | 2.0 | 2.1 | -0.1 | 1.43 (1.16, 1.75) |
| HX_COVID | History of COVID-19 | 13.8 | 14.3 | 13.1 | 1.2 | 1.00 (0.92, 1.08) |
| MA | MA (versus FFS) | 36.5 | NA | NA | NA | 1.02 (0.96, 1.09) |

THA/TKA Model Performance

Table 4.2.4 presents model performance for the THA/TKA measure across three scenarios: the FFS-only cohort with CC-based risk variables, the FFS+MA cohort with CC-based risk variables, and the FFS+MA cohort with ICD-10-based risk variables. Predictive ability and c-statistics were similar between the FFS-only and FFS+MA cohorts using the original CC-based variables. For the MA+FFS cohort, the model using reselected ICD-10-based risk variables also had a similar predictive ability and c-statistic compared to the original CC-based model. Calibration performance was generally acceptable across all modeling approaches in the overall cohort and in subgroups, including male versus female, MA versus FFS, and quartiles of hospital volume (figures not shown).

Table 4.2.4: THA/TKA Complication: Predictive Ability and C-Statistics Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022

| Value | FFS-only cohort with CC-based risk variables | FFS+MA cohort with CC-based risk variables | FFS+MA cohort with ICD-10-based risk variables |
|--|--|--|--|
| Predictive Ability, % (lowest decile – highest decile) | 1.1 – 8.0 | 1.1 – 8.5 | 1.3 – 8.6 |
| c-statistic | 0.67 | 0.67 | 0.67 |

Note: These statistics were calculated using the patient-level logistic model.

Risk-Standardized Complication Rates for THA/TKA

Tables 4.2.5 and 4.2.6 present distribution of hospital volume, SCR, and RSCR for all hospitals (Table 4.2.5) and for hospitals with 25 or more eligible admissions (Table 4.2.6). Numbers of hospitals and admissions were higher in the combined FFS+MA data compared to the FFS-only data. With the addition of MA data, 183 additional hospitals were included in the measure (3,007 versus 2,824) and 398 additional hospitals met the 25 or more admissions cutoff for public reporting (1,270 versus 872). For all hospitals, the mean RSCR was 3.3% for the FFS-only cohort with CC-based risk variables, 3.5% for the FFS+MA cohort with CC-based risk variables, and 3.5% for the FFS+MA cohort with reselected ICD-10-based risk variables. Among hospitals with 25 or more admissions, mean RSCRs were 3.2%, 3.4%, and 3.4%, respectively.

Table 4.2.5: THA/TKA Complication: Hospital Volume, Standardized Complication Ratio (SCR), and Risk-Standardized Complication Rate (RSCR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for All Hospitals

| Value | FFS-Only cohort with CC-based risk variables (N= 2,824 hospitals) | | FFS+MA cohort with CC-based risk variables (N= 3,007 hospitals) | | FFS+MA cohort with ICD-10-based risk variables (N= 3,007 hospitals) | |
|------------------------|--|----------------------------|--|----------------------------|--|----------------------------|
| | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) |
| Hospital Volume | 33.1 (86.6) | 11 (4, 31) | 48.9 (108.1) | 18 (6, 50) | 48.9 (108.1) | 18 (6, 50) |
| SCR | 1.01 (0.13) | 0.99 (0.95, 1.06) | 1.01 (0.16) | 0.99 (0.93, 1.09) | 1.01 (0.16) | 0.99 (0.93, 1.09) |
| RSCR (%) | 3.3 (0.4) | 3.2 (3.1, 3.5) | 3.5 (0.5) | 3.4 (3.2, 3.7) | 3.5 (0.5) | 3.4 (3.2, 3.7) |

Table 4.2.6: THA/TKA Complication: Hospital Volume, Standardized Complication Ratio (SCR), and Risk-Standardized Complication Rate (RSCR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions

| Value | FFS-Only cohort with CC-based risk variables (N= 872 hospitals) | | FFS+MA cohort with CC-based risk variables (N= 1,270 hospitals) | | FFS+MA cohort with ICD-10-based risk variables (N= 1,270 hospitals) | |
|------------------------|--|----------------------------|--|----------------------------|--|----------------------------|
| | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) | Mean (SD) | Median (25% Q1, 75% Q3) |
| Hospital Volume | 89.3 (140.1) | 53 (35, 98) | 103.6 (149.9) | 61 (38, 111) | 103.6 (149.9) | 61 (38, 111) |
| SCR | 0.99 (0.19) | 0.96 (0.87, 1.09) | 1.00 (0.21) | 0.97 (0.85, 1.11) | 1.00 (0.21) | 0.97 (0.86, 1.11) |
| RSCR (%) | 3.2 (0.6) | 3.1 (2.8, 3.6) | 3.4 (0.7) | 3.3 (2.9, 3.8) | 3.4 (0.7) | 3.3 (2.9, 3.8) |

Measure Reliability for THA/TKA

Between hospital variance and STNR for the measure score comparing the addition of MA admissions to the FFS-only cohort and reselected ICD-10-based variables to the CC-based variables in the FFS+MA cohort are noted in [Table 4.2.7](#). Median STNR, calculated based on between hospital variance and hospital volume, was 0.711 for the FFS-only cohort with CC-based risk variables, 0.751 for the FFS+MA cohort with CC-based risk variables, and 0.748 for the FFS+MA cohort with reselected ICD-10-based risk variables.

Table 4.2.7: THA/TKA Complication: Between Hospital Variance and Signal-to-Noise Reliability (STNR) Comparing FFS-only and FFS+MA Cohorts with CC-Based and ICD-10-Based Risk Variables, CY 2022, for Hospitals with 25 or More Admissions

| Value | FFS-only cohort with CC-based risk variables | FFS+MA cohort with CC-based risk variables | FFS+MA cohort with ICD-10-based risk variables |
|---------------------------|--|--|--|
| Number of Hospitals | 872 | 1,270 | 1,270 |
| Between Hospital Variance | 0.152 | 0.164 | 0.161 |
| STNR: Median (Q1, Q3) | 0.711 (0.619, 0.819) | 0.751 (0.654, 0.847) | 0.748 (0.651, 0.845) |

Change in Hospital Performance for THA/TKA

Table 4.2.8 shows the quintile shifts in RSCR across hospitals with at least 25 FFS admissions for the THA/TKA measure in the combined FFS+MA cohort as compared to the FFS-only cohort in hospitals for the model with the original CC-based variables. After adding MA admissions to the FFS-only cohort, approximately half (56.1%) of hospitals remained in the same performance quintile, and 92.0% remained within +/- 1 quintile. Correlation between hospital RSCRs was 0.85. As hospitals' proportion of MA admissions increased, fewer hospitals remained in the same performance quintile (80.3% among hospitals in the lowest quintile of percent MA admissions; 44.3% of hospitals in the highest quintile of percent of MA admissions). As hospital volume increased, the trend in RSCR shifts was less pronounced.

Table 4.2.9 shows the quintile shifts in RSCR across hospitals with at least 25 FFS admissions for the THA/TKA measure after both measure updates, comparing the combined FFS+MA cohort using the reselected ICD-10-based risk variables to the FFS-only cohort using the CC-based variables. With the addition of the MA admissions and the ICD-10-based risk variables, 55.8% of hospitals remained in the same performance quintile and 91.3% remained within +/- 1 quintile. Correlation between hospital RSCRs was 0.85. As hospitals' proportion of MA admissions increased, fewer hospitals remained in the same performance quintile (77.5% among hospitals in the lowest quintile of percent MA admissions; 46.6% of hospitals in the highest quintile of percent of MA admissions).

Table 4.2.8: Shifts in RSCR Hospital Performance Quintile Rankings for THA/TKA, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-Only Cohort to the FFS+MA Cohort, CC-Based Variables, CY 2022

| Description | Same quintile (%) | ±1 quintile (%) | Correlation |
|-----------------------------|-------------------|-----------------|-------------|
| Overall | 56.1 | 92.0 | 0.85 |
| By Percent of MA Admissions | | | |
| Q1: 0.0% – 13.2% | 80.3 | 97.7 | 0.98 |
| Q2: 13.3% – 23.6% | 61.9 | 96.6 | 0.89 |
| Q3: 23.7% – 33.3% | 50.6 | 92.5 | 0.86 |
| Q4: 33.5% – 44.4% | 43.4 | 88.0 | 0.79 |
| Q5: 44.4% – 89.2% | 44.3 | 85.1 | 0.81 |
| By MA+FFS Admission Volume | | | |
| Q1: 25 – 47 admissions | 64.0 | 95.4 | 0.86 |
| Q2: 48 – 67 admissions | 52.4 | 95.9 | 0.84 |
| Q3: 68 – 99 admissions | 54.2 | 93.3 | 0.87 |
| Q4: 100 – 179 admissions | 49.4 | 87.4 | 0.83 |
| Q5: 180 – 3,515 admissions | 60.3 | 87.9 | 0.84 |

Note: Quintile percentages represent the percent of hospitals that stayed in their same (1st column) or within one (2nd column) performance quintile ranking after the addition of MA admissions.
Total N= 872 representing hospitals with 25 or more FFS admissions

Table 4.2.9: Shifts in RSCR Hospital Performance Quintile Rankings for THA/TKA, Overall and Based on Hospitals' Percentages of MA Admissions and Total Admission Volume, Comparing FFS-only Cohort with CC-Based variables to the FFS+MA Cohort with Reselected ICD-10-Based Risk Variables, CY 2022

| Description | Same quintile (%) | ±1 quintile (%) | Correlation |
|-----------------------------|-------------------|-----------------|-------------|
| Overall | 55.8 | 91.3 | 0.85 |
| By Percent of MA Admissions | | | |
| Q1: 0.0% – 13.2% | 77.5 | 97.1 | 0.97 |
| Q2: 13.3% – 23.6% | 61.9 | 95.5 | 0.90 |
| Q3: 23.7% – 33.3% | 47.7 | 90.8 | 0.85 |
| Q4: 33.5% – 44.4% | 45.7 | 88.6 | 0.78 |
| Q5: 44.4% – 89.2% | 46.6 | 84.5 | 0.80 |
| By MA+FFS Admission Volume | | | |
| Q1: 25 – 47 admissions | 59.4 | 94.9 | 0.86 |
| Q2: 48 – 67 admissions | 54.7 | 94.7 | 0.83 |
| Q3: 68 – 99 admissions | 52.0 | 93.3 | 0.88 |
| Q4: 100 – 179 admissions | 50.0 | 87.9 | 0.84 |
| Q5: 180 – 3,515 admissions | 63.2 | 85.6 | 0.81 |

Note: Quintile percentages represent the percent of hospitals that stayed in their same (1st column) or within one (2nd column) performance quintile ranking after the addition of MA admissions and with reselected ICD-10-based risk variables.
Total N=872, representing hospitals with 25 or more FFS admissions

5. REFERENCES

1. Centers for Medicare & Medicaid Services. Encounter Data Submission and Processing Guide 2022. Accessed January 31, 2024. [https://www.csscooperations.com/internet/csscw3_files.nsf/F2/2022ED_Submission_Processing_Guide_20221130.pdf/\\$FILE/2022ED_Submission_Processing_Guide_20221130.pdf](https://www.csscooperations.com/internet/csscw3_files.nsf/F2/2022ED_Submission_Processing_Guide_20221130.pdf/$FILE/2022ED_Submission_Processing_Guide_20221130.pdf)
2. Ochieng N, Freed M, Biniek JF, Damico A, Neuman T. Medicare Advantage in 2023: Enrollment Update and Key Trends. Accessed January 31, 2024. <https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2023-enrollment-update-and-key-trends/>
3. Congressional Budget Office. Congressional Budget Office Baseline Projections May 2022. Accessed January 31, 2024. <https://www.cbo.gov/system/files/2022-05/51302-2022-05-medicare.pdf>
4. Ochieng N, Biniek JF. Beneficiary Experience, Affordability, Utilization, and Quality in Medicare Advantage and Traditional Medicare: A Review of the Literature. KFF. Accessed January 31, 2024. <https://www.kff.org/medicare/report/beneficiary-experience-affordability-utilization-and-quality-in-medicare-advantage-and-traditional-medicare-a-review-of-the-literature/>
5. Medicare Payment Advisory Commission. March 2022 report to the Congress: Medicare Payment Policy: The Medicare Advantage program: Status Report and mandated report on dual-eligible special needs plans. Accessed January 31, 2024. https://www.medpac.gov/wp-content/uploads/2022/03/Mar22_MedPAC_ReportToCongress_Ch12_SEC.pdf
6. Pope GC, Ellis RP, Ash AS, et al. Diagnostic cost group hierarchical condition category models for Medicare risk adjustment. Final Report to the Health Care Financing Administration under Contract Number 500-95-048. 2000. Accessed January 31, 2024. http://www.cms.hhs.gov/Reports/downloads/pope_2000_2.pdf
7. Pope GC, Kautter J, Ingber MJ, Freeman S, Sekar R, Newhart C. Evaluation of the CMS-HCC Risk Adjustment Model: Final Report. 2011. Accessed January 31, 2024. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/downloads/evaluation_risk_adj_model_2011.pdf
8. Krumholz HM, Coppi AC, Warner F, et al. Comparative effectiveness of new approaches to improve mortality risk models from Medicare claims data. *JAMA Network Open*. 2019;2(7):e197314-e197314.
9. Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation (YNHHSC/CORE). *Methodology Report, Measure Testing Report, and Risk-Adjustment Report: Clinician and Clinician Group Risk-standardized Hospital Admission Rates for Patients with Multiple Chronic Conditions*. 2019. Centers for Medicare & Medicaid Services: *Measure Instrument Development and Support; Development, Reevaluation, and Implementation of Outpatient Outcome/Efficiency Measures; Contract Number HHSM-75FCMC18D0042, Task Order HHSM-75FCMC19F0002*. 2019.
10. Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation (YNHHSC/CORE). 2023 Condition-Specific Mortality Measures Updates and Specifications Report. Accessed February 14, 2024. <https://qualitynet.cms.gov/inpatient/measures/mortality/methodology>